SCNI Valuation

Scinai Immunotherapeutics Ltd

Add to Watchlist

Advanced Chart

1.530

+0.07(4.795%)1D

Overview
Forecast
Valuation
Earnings

SCNI Relative Valuation

SCNI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SCNI is overvalued; if below, it's undervalued.

Historical Valuation

Scinai Immunotherapeutics Ltd (SCNI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -217.35. The fair price of Scinai Immunotherapeutics Ltd (SCNI) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.53

Fair

0.00

Trailing

Forward

0.00

EV/EBITDA

Scinai Immunotherapeutics Ltd. (SCNI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.56

EV/EBIT

Scinai Immunotherapeutics Ltd. (SCNI) has a current EV/EBIT of -0.56. The 5-year average EV/EBIT is -2.61. The thresholds are as follows: Strongly Undervalued below -9.01, Undervalued between -9.01 and -5.81, Fairly Valued between 0.58 and -5.81, Overvalued between 0.58 and 3.78, and Strongly Overvalued above 3.78. The current Forward EV/EBIT of -0.56 falls within the Historic Trend Line -Fairly Valued range.

0.00

Scinai Immunotherapeutics Ltd. (SCNI) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Scinai Immunotherapeutics Ltd. (SCNI) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

-0.07

P/FCF

Scinai Immunotherapeutics Ltd. (SCNI) has a current P/FCF of -0.07. The 5-year average P/FCF is -0.26. The thresholds are as follows: Strongly Undervalued below -1.40, Undervalued between -1.40 and -0.83, Fairly Valued between 0.31 and -0.83, Overvalued between 0.31 and 0.88, and Strongly Overvalued above 0.88. The current Forward P/FCF of -0.07 falls within the Historic Trend Line -Fairly Valued range.

Scinai Immunotherapeutics Ltd (SCNI) has a current Price-to-Book (P/B) ratio of 0.30. Compared to its 3-year average P/B ratio of 0.15 , the current P/B ratio is approximately 102.42% higher. Relative to its 5-year average P/B ratio of -10.42, the current P/B ratio is about -102.88% higher. Scinai Immunotherapeutics Ltd (SCNI) has a Forward Free Cash Flow (FCF) yield of approximately -444.30%. Compared to its 3-year average FCF yield of -246.32%, the current FCF yield is approximately 80.38% lower. Relative to its 5-year average FCF yield of -160.51% , the current FCF yield is about 176.81% lower.

0.30

P/B

Median3y

0.15

Median5y

-10.42

-444.30

FCF Yield

Median3y

-246.32

Median5y

-160.51

Competitors Valuation Multiple

The average P/S ratio for SCNI's competitors is 0.09, providing a benchmark for relative valuation. Scinai Immunotherapeutics Ltd Corp (SCNI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SCNI.O

Scinai Immunotherapeutics Ltd

Qualigen Therapeutics Inc

Loss

3.03M

ENVB.O

Enveric Biosciences Inc

Loss

3.67M

PMCB.O

PharmaCyte Biotech Inc

Performance Decomposition

Market capitalization of SCNI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SCNI in the past 1 year is driven by Unknown.